Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure In India To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 1 of 2)
Sanofi-Aventis has had an interesting past in India from having a discovery research center to creating some of the most recognized pharmaceutical brands. But its Managing Director Shailesh Ayyangar is not resting on those achievements. The senior executive who started with Ranbaxy and also worked at SmithKline Beecham in key positions is now taking up the daunting challenge of creating a new paradigm in the rural centers of India. An exercise that requires huge investments, navigation of unseen opposition along with perseverance to witness a real change excites Ayyangar. In a rare interview, Ayyangar spoke to PharmAsia News' India Bureau about the company's rural markets strategy, creating brands, doing research deals and also about buying out "strategically important" companies.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
